Eurobio Scientific terminates its liquidity contract

On March 4, 2025, Eurobio Scientific, a French player in in vitro medical diagnostics, announced the termination of its liquidity contract with TP ICAP. This contract, initially set up on April 10, 2019, had been suspended since August 1, 2024. At the end date, the liquidity account did not contain any securities but had €231,501.72 in cash.

When this liquidity contract was established, Eurobio Scientific had made available 31,573 shares and a cash amount of 55,902.07 euros. This termination marks a step in the management of the liquidity of the company's shares. Eurobio Scientific continues its activities in the medical sector on Euronext Growth Paris.